58 results about "Nerve growth factor" patented technology

The invention discloses a culture medium for adipose-derived stem cells, and particularly relates to the technical field of stem cell culture. The culture medium comprises a basic culture medium and nerve-vascular niche components, wherein the basic culture medium comprises DMEM / F12, 10% of human-derived platelet lysate and 1% of antibiotic solution; the nerve-vascular niche comprises the following components: a Slit3 recombinant protein, a nerve growth factor-beta, a glial cell-derived neurotrophic factor, a lysyl oxidase inhibitor, dexamethasone, 3-isobutyl-1-methylxanthine and insulin. The traditional fetal calf serum is replaced by the human-derived platelet lysate, so that the risks of immunological rejection and pathogen pollution are avoided; through the synergistic effect of nerve-vessel niche factors, blood vessel maturation and innervation are promoted, programmed mechanical stretching culture is combined, the adipogenic differentiation efficiency of adipose-derived stem cells is remarkably improved, and engineered adipose tissue which is huge in lipid droplet, compact in structure and provided with a nerve-vessel network is formed.

The present application relates to a nutritional composition, a product comprising the same and use thereof in the preparation of a product for alleviating synaptic plasticity impairment of a body. The nutritional composition comprises: docosahexaenoic acid (DHA) and / or a metabolic precursor thereof, sodium hyaluronate (SH), and lactoferrin (LF). When docosahexaenoic acid (DHA), sodium hyaluronate (SH) and lactoferrin (LF) are used in combination, they can synergistically alleviate synaptic plasticity impairment of a body, in particular, increase nerve growth factor (NGF) content and / or brain-derived neurotrophic factor (BDNF) content in PC12 cells of the body, and / or increase expression of synaptic-related proteins in PC12 cells of the body.

The present application relates to a kind of water gel support prepared by self-assembled polypeptide and the use of support obtained therefrom, the preparation method includes: 1) self-assembled peptide sequence is linked nerve growth factor analog peptide by covalent bond to obtain bonded functional polypeptide;2) macrophage is separated and cultured, and is induced to be " alternative activation " anti-inflammatory M2 macrophage, obtain culture supernatant and carry out filtration, obtain filtered cell culture supernatant;3) filtered cell culture supernatant is mixed with bonded functional polypeptide, obtain mixed solution and adjust the concentration of the mixed solution, the bonded functional polypeptide self-assembles and forms water gel support.The present application uses M2 macrophage condition culture supernatant to construct regenerative microenvironment, combines polypeptide functional water gel support, realizes better overall interaction, and prepares the water gel support that can supplement and regulate nerve regeneration, the support can promote nerve cell regeneration behavior, provides new selection for tissue engineering biomaterials.

The invention relates to application of graphene-(RADA-IKVAV)-pranoprofen, eye drops and a preparation method of the eye drops. The invention relates to graphene-(RADA-IKVAV)-pranoprofen, the graphene-(RADA-IKVAV)-pranoprofen comprises graphene-polyacrylic acid, self-assembled oligopeptide RADA-IKVAV and pranoprofen, the self-assembled oligopeptide RADA-IKVAV is connected with the graphene-polyacrylic acid through a chemical bond, and the pranoprofen is loaded on the surface of the graphene-polyacrylic acid. The eye drops provided by the invention comprise graphene-(RADA-IKVAV)-pranoprofen, so that the drug loading capacity of pranoprofen in the eye drops is increased, the bioavailability of drugs is improved, and the eye drops are used for inhibiting eye inflammation; the coupled oligopeptide RADA-IKVAV simulates an extracellular environment, provides a suitable microenvironment for eyes, promotes nerve repair and regeneration by influencing nerve growth factors, and promotes optic nerve repair.

The present disclosure provides recombinantly manufactured fusion proteins comprising a nerve growth factor (NGF) protein fragment or an analog thereof linked to a canine Fc fragment. Embodiments include the administration of the fusion proteins to patients to reduce pain symptoms in dogs suffering from a pain-associated ailment such as osteoarthritis. Exemplary Fc fusion proteins and pharmaceutical formulations of exemplary Fc fusion proteins are provided, in addition to methods of use and preparation.

The invention discloses a spinal cord injury repair multifunctional composite material and a preparation method and application thereof. The material is prepared from chitosan-loaded nano manganese dioxide, resveratrol and nerve growth factors. The method comprises the following steps: adding a dispersing agent and modified nano-manganese dioxide into a chitosan solution, and then adding a resveratrol solution and a diluted nerve growth factor solution into the chitosan solution to obtain a mixed solution; finally, the mixed solution is subjected to freeze drying treatment, and the spinal cord injury repairing multifunctional composite material is obtained. The spinal cord injury repair multifunctional composite material can be used as a medical stent material for treating spinal cord injury. Through the innovation of drug controlled release (pH response + slow release) and multi-mechanism cooperation (oxidation resistance / inflammation resistance / regeneration), the limitation of a single mode of spinal cord injury treatment is broken through, and a comprehensive strategy with a wide application prospect is provided for SCI repair.

The present invention relates to a method for attenuating retinal cell damage and other neuronal cell damage outside the central nervous system associated with reduced supply of neurotrophin, i.e., nerve growth factor (NGF), induced by glaucoma and other forms of neurodegeneration by orally administering a therapeutically effective amount of an aqueous extract of spearmint to a subject.

Disclosed herein are compounds and pharmaceutical compositions useful for treating, preventing, reducing, or ameliorating diseases or conditions associated with neurodegenerative disorders. Without being bound by theory, the disclosed compounds and compositions are believed to selectively target tropomyosin receptor kinase A (TrkA) receptor-mediated pro-survival signaling pathways or the nerve growth factor (NGF) or the neurosteroid dehydroepiandrosterone (DHEA) and may prevent, treat, reduce, or ameliorate neurodegeneration.

This invention belongs to the pharmaceutical field and relates to a human nerve growth factor composition. This invention provides a human nerve growth factor composition that can be administered via multiple routes, maintains good stability without cryopreservation, and does not require fixed accessories, simplifying operation and improving the convenience of medication.

This invention discloses an injectable hydrogel for long-term sustained release of NGF and CNTF, its preparation method, and its application in visual system diseases. The bioactive factor sustained-release hydrogel of this invention comprises a hydrogel matrix and bioactive factor microspheres loaded on the matrix; the raw materials for preparing the hydrogel matrix include chitosan, type II collagen, and hyaluronic acid; the bioactive factor microspheres comprise an inner core and a capsule wall, the inner core being a bioactive factor selected from one or both of ciliary neurotrophic factor and nerve growth factor, and the capsule wall being a polylactic acid-glycolic acid copolymer. This hydrogel can achieve long-term stable release of NTF, activating endogenous neural stem cells in the retina to generate new retinal ganglion cells. It exhibits high safety, good injectability, and a long sustained-release period, and can be used to prepare drugs for treating visual system diseases such as glaucoma, optic nerve damage, and macular degeneration.

The invention discloses a resveratrol and nerve growth factor loaded chitosan-polydopamine modified 3D printing biological material as well as a preparation method and application thereof in spinal cord injury repair, the structure and function of the biological material simulate a natural extracellular matrix (ECM) tissue structure to fill cavities in a spinal cord injury area, and tissue regeneration can be guided; meanwhile, the compound can be used as a carrier of medicines, cells or bioactive factors. According to the material, a three-dimensional porous PLA support with an accurate structure is printed through a fused deposition modeling (FDM) technology to serve as a carrier for cell compatibility and physical supporting, CS is loaded in the three-dimensional porous PLA support through a freeze drying technology, PDA carrying NGF is loaded on the surface of the three-dimensional porous PLA support, Res is loaded through the physical adsorption effect, and the multifunctional 3D biological composite material for spinal cord injury repair is prepared. Through the synergistic effect of anti-inflammatory, anti-oxidation, anti-apoptosis and other ways, a microenvironment beneficial to nerve regeneration is created together, and functional recovery after spinal cord injury is significantly promoted.

Provided herein are compositions and methods for the inhibition of nerve growth factor (NGF) and the treatment / prevention of atrial fibrillation. In particular, inhibitors of NGF expression are administered to the myocardial tissue of a subject to treat or prevent atrial fibrillation and / or autonomic nerve sprouting in the atria.

The invention discloses application of an ophthalmic preparation containing a recombinant human beta-nerve growth factor. The ophthalmic preparation can be used for treating dry eyes. The ophthalmic preparation containing the recombinant human beta-nerve growth factor comprises 5 to 1000 [mu] g / ml of the recombinant human beta-nerve growth factor, 20 to 70 mg / ml of trehalose, 5 to 30 mg / ml of mannitol and 1 to 13 mg / ml of polyvinyl alcohol.

The invention relates to an anti-recombinant cat nerve growth factor egg yolk antibody as well as a preparation method and application thereof. The preparation method comprises the following steps: preparing an antigen recombinant cat nerve growth factor by utilizing genetic engineering prokaryotic expression; immunizing laying hens by using the antigen recombinant cat nerve growth factors, and collecting eggs; the method comprises the following steps: cleaning eggs, separating yolk, mixing with normal saline to obtain a first mixed solution, adding chloroform into the first mixed solution, carrying out water bath to obtain a second mixed solution, centrifuging to obtain a yolk antibody extracting solution, and further purifying the yolk antibody extracting solution to obtain the yolk antibody, the amino acid of the recombinant cat nerve growth factor is the 113th-238th amino acid of the cat nerve growth factor, the gene sequence for coding the recombinant cat nerve growth factor is shown as SEQ ID NO: 8, and the prepared egg yolk antibody has excellent antigenicity, is more convenient to obtain, can effectively reduce the cost, is more beneficial to production, and has wide application prospects.

The present invention relates to compositions comprising modified virus-like particles (VLPs) of Cucumber Mosaic Virus (CMV), and in particular to modified VLPs of CMV comprising chimeric CMV polypeptides which comprises a stretch of consecutive negative amino acids selected from aspartic acid or glutamic acid to which nerve growth factor (NGF) antigens are linked as well as pharmaceutical compositions thereof, which compositions preferably serve as vaccine platform for generating immune responses, in particular antibody responses, against said NGF antigens linked to the modified CMV VLPs.

The present invention relates to a cosmetic composition comprising a combination of nerve growth factor (NGF) inhibitors, that is particularly of use in the topical treatment of pruritus, in particular, that observed in the case of psoriasis or of atopic dermatitis, of chronic urticaria and also of senile pruritus. The invention is directed towards a composition comprising an ambora extract and a green tea extract.

The present disclosure provides recombinantly manufactured fusion proteins comprising a nerve growth factor (NGF) protein fragment or an analog thereof linked to a canine Fc fragment. Embodiments include the administration of the fusion proteins to patients to reduce pain symptoms in dogs suffering from a pain-associated ailment such as osteoarthritis. Exemplary Fc fusion proteins and pharmaceutical formulations of exemplary Fc fusion proteins are provided, in addition to methods of use and preparation.

The invention discloses a biomarker for diagnosing pulmonary fibrosis and application of the biomarker, and belongs to the technical field of biomarkers in clinical medicine. The biological marker for preparing and diagnosing pulmonary fibrosis is a nerve growth factor NGF, the nerve growth factor NGF can remarkably promote differentiation of lung fibroblast MRC5 cells, and along with expression increase of a receptor TrkA of the lung fibroblast MRC5 cells, the migration capacity and the multiplication capacity of the lung fibroblast MRC5 cells are remarkably enhanced. Meanwhile, the NGF also aggravates the formation of the BLM-induced pulmonary fibrosis of the mouse. Therefore, the nerve growth factor NGF as the biomarker has accurate and specific detection and auxiliary diagnosis on pulmonary fibrosis, especially idiopathic pulmonary fibrosis (IPF).

The present application relates to the technical field of hydrogel composite scaffold, in particular to a layer-by-layer self-assembled oxygen-responsive liposome hydrogel composite scaffold and a preparation method, hydrophilic nerve growth factor (GDNF) is encapsulated in the aqueous internal region of the liposome, and low-oxygen-responsive vascular endothelial growth factor (VEGF) plasmid and polyarginine are coated by electrostatic adsorption layer by layer (LBL), so as to construct an intelligent responsive LBL double-drug cationic liposome; subsequently, hyaluronic acid-carboxymethyl cellulose sodium (HA-CMC) hydrogel is introduced to carry the liposome to form a double-drug composite scaffold, so as to enhance the adhesion and local release characteristics of the composite scaffold on the wound surface. In a diabetic animal model, the LBL liposome loaded on the HA / CMC hydrogel can significantly accelerate wound healing, promote collagen deposition, angiogenesis and nerve fiber regeneration, and regulate the polarization of macrophages to the repair phenotype, thereby reducing the inflammatory response and achieving functional tissue repair.

The present disclosure relates to nerve growth factor (NGF) for use in the prevention or treatment of neurodevelopmental disabilities associated with neonatal hypoxic-ischemic encephalopathy in a subject, wherein the NGF is administered intranasally to the subject.

Provided are methods of assessing future onset or progression of an ocular health condition in a subject, comprising obtaining a tear fluid sample from the subject; measuring, in the tear fluid sample, concentrations of a plurality of biomarkers of a biomarker panel, wherein the biomarker panel comprises at least two or more biomarkers from the group consisting of Nerve Growth Factor (NGF), Interleukin-8 (IL-8), Tumor Necrosis Factor-Alpha (TNF-α), and Interleukin- 13 (IL-13); comparing the measured biomarker concentrations to condition-specific signature criteria; and based on the comparison, identifying the subject as having proclivity to future onset or progression of: (i) Contact Lens Discomfort (CLD) when the measured NGF concentration and the measured IL-8 concentration meet a first condition-specific signature criterion, or (ii) Dry Eye Disease (DED) when the measured NGF concentration, the measured TNF-α concentration, and the measured IL-13 concentration meet a second condition-specific signature criterion.

The present disclosure provides recombinantly manufactured fusion proteins comprising a nerve growth factor (NGF) protein fragment or an analog thereof linked to a canine Fc fragment. Embodiments include the administration of the fusion proteins to patients to reduce pain symptoms in dogs suffering from a pain-associated ailment such as osteoarthritis. Exemplary Fc fusion proteins and pharmaceutical formulations of exemplary Fc fusion proteins are provided, in addition to methods of use and preparation.

The present application relates to a kind of steroid compound and its application in treating neurodegenerative diseases, the steroid compound has the structure shown in formula I: The steroid compound of structure I is isolated from the whole grass of Solanum nigrum by yeast fermentation for the first time, it shows better neurotrophic factor (NGF) activity and acetylcholinesterase inhibitory activity, is expected to be developed as the drug or functional food of neurotrophic and neuroprotective function, for treating neurodegenerative diseases (such as senile dementia).

Some embodiments of the present disclosure relate to one or more compositions that upregulate the production of one or more sequences of mRNA. The sequences of mRNA may encode for translation of a target biomolecule, thereby causing an increase in bioavailability of the target biomolecule within a subject that is administered the one or more compositions. In some embodiments of the present disclosure, the target biomolecule is a fusion protein with an Fc fragment, such as a toll-like receptor 3-Fc (TLR3-Fc). In some embodiments of the present disclosure, the target biomolecule is toll-like receptor 9-Fc (TLR9-Fc). In some embodiments of the present disclosure, the target biomolecule is deoxyribonuclease I-Fc (DNAse I-Fc). In some embodiments of the present disclosure, the target biomolecule is neural growth factor-Fc (NGF-Fc). In some embodiments of the present disclosure, the target biomolecule is insulin-Fc.

The invention discloses a micro electrical stimulation nerve conduit and a preparation method thereof. The nerve conduit prepared by the invention has good medical value on nerve injury repair and nerve transplantation function repair through various ways of establishing a mechanical space, supplementing nerve growth factors, performing electrical stimulation on nerve development and the like. The whole nerve conduit is made of a degradable material and is degraded in vivo after the effect is achieved, and a secondary mechanical taking operation is avoided. Metal is embedded in the two ends of the catheter, micro-current stimulation is generated in a self-source mode by utilizing the corrosion potential difference of different metals and taking body fluid as electrolyte, nerve development is promoted, and the safety and miniaturization of the catheter with the same effect are improved. The fiber membrane is arranged on the inner-layer tube body, so that the carried nerve growth factors can be slowly released, and nutrients required by nerve growth can be provided; the fiber membrane is rolled to be cylindrical, so that the nerve can grow along the catheter in an adhesion manner, and the regeneration efficiency of nervous tissues is improved.

The present disclosure provides recombinantly manufactured fusion proteins comprising a nerve growth factor (NGF) protein fragment or an analog thereof linked to a canine Fc fragment. Embodiments include the administration of the fusion proteins to patients to reduce pain symptoms in dogs suffering from a pain-associated ailment such as osteoarthritis. Exemplary Fc fusion proteins and pharmaceutical formulations of exemplary Fc fusion proteins are provided, in addition to methods of use and preparation.

The present invention relates to a process for production of nerve growth factor (NGF) and muteins thereof, in particular muteins of human NGF. The process of the present invention yields nerve growth factor (NGF) and muteins thereof, e.g. from recombinant sources, at high purity. Aspects related to the process of the present invention, such as muteins obtainable thereby, are also described. The respective muteins may be characterized e.g. by improved detectability and / or reduced nociceptive activity, compared to wildtype human NGF.